CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on developing chimeric engulfment receptor T-cell therapies for the treatment of hematologic malignancies. The company's 424B4 prospectus was filed with the SEC in October 2021, marking its entry into the public markets in the life sciences and cell therapy sector. CERO's lead program centers on engineered T-cell constructs designed to target and eliminate cancer cells through novel receptor biology. As a publicly traded therapeutics holding company, CERO operates at the intersection of immunology and oncology drug development. Investors and analysts tracking CERO's regulatory milestones, clinical pipeline, and capital activity can access comprehensive data and filings by signing up for full coverage on SpacDesk.